Biopharmaceutical firm OnCusp Therapeutics has initiated a Phase 1 clinical trial for CUSP06, an innovative CDH6-directed antibody-drug conjugate (ADC).

Innate Pharma SA has initiated a Phase 1/2 clinical trial to evaluate the safety and tolerability of IPH6501.

Kura Oncology, Inc. has commenced the first patient dosing with KO-2806, a farnesyl transferase inhibitor (FTI), combined with tyrosine kinase inhibitor (TKI) cabozantinib.

Syncromune®, Inc., will showcase groundbreaking data from their Phase 1 clinical trials of SYNC-T, a pioneering in situ platform therapy tailored for solid tumor cancers.

Sionna Therapeutics, based in Massachusetts, has successfully concluded a Series C funding round, raising $182 million.

Encouraging interim results have emerged from the Phase 1 clinical trial of ALG.APV-527, a drug developed by Alligator Bioscience AB and Aptevo Therapeutics.

The therapy involves the use of genetically modified T cells that target a specific protein, interleukin-13 receptor alpha 2 (IL13Rα2), which is overexpressed in glioblastomas.

This plan aims to optimize resource allocation towards key projects like the ongoing KB-0742 phase 1/2 study by assessing a new dosing schedule.

Neurona Therapeutics has announced an upcoming presentation of new data from their Phase I/II clinical trial for NRTX-1001.

A clinical-stage CAR-T company is currently enrolling patients to trial SynKIR™-110, an innovative treatment option for ovarian cancer, mesothelioma, and cholangiocarcinoma.

Debiopharm, has initiated a Phase 1 study expansion to evaluate the safety, tolerability, and potential anti-tumor effects of Debio 0123, a potent WEE1 inhibitor.

MB-101 demonstrated a high safety profile and significant therapeutic potential in treating patients with recurrent and refractory malignant glioma, including those with glioblastoma.